Brokerages Set UroGen Pharma Ltd. (NASDAQ:URGN) Target Price at $43.70

Shares of UroGen Pharma Ltd. (NASDAQ:URGN) have received an average rating of “Buy” from the six analysts that are covering the stock, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $43.70.

Several equities analysts have recently commented on URGN shares. EF Hutton Acquisition Co. I raised UroGen Pharma to a “strong-buy” rating in a research report on Monday, October 14th. D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price objective on shares of UroGen Pharma in a report on Friday, December 6th. Oppenheimer reissued an “outperform” rating and set a $40.00 target price on shares of UroGen Pharma in a report on Wednesday, October 16th. Finally, HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of UroGen Pharma in a research note on Tuesday, October 15th.

Institutional Investors Weigh In On UroGen Pharma

Large investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. increased its holdings in shares of UroGen Pharma by 90.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,100 shares of the company’s stock valued at $103,000 after acquiring an additional 3,856 shares in the last quarter. BNP Paribas Financial Markets grew its position in UroGen Pharma by 221.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after purchasing an additional 5,890 shares during the period. ProShare Advisors LLC bought a new stake in UroGen Pharma during the 2nd quarter valued at $199,000. Intech Investment Management LLC acquired a new position in UroGen Pharma during the third quarter worth $155,000. Finally, Verition Fund Management LLC bought a new position in shares of UroGen Pharma in the third quarter valued at $168,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

UroGen Pharma Price Performance

NASDAQ URGN opened at $10.70 on Tuesday. The firm’s 50 day moving average is $11.74 and its 200-day moving average is $13.60. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. UroGen Pharma has a 12-month low of $10.26 and a 12-month high of $20.70. The company has a market capitalization of $250.96 million, a PE ratio of -3.40 and a beta of 1.06.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.29. The firm had revenue of $25.20 million during the quarter, compared to analyst estimates of $24.22 million. During the same quarter in the prior year, the business earned ($0.68) EPS. Equities research analysts anticipate that UroGen Pharma will post -3.1 earnings per share for the current fiscal year.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.